Directors and CXOs

• October 2001 Registered as an attorney (Osaka Bar Association) Joined Habataki Law Office
• November 2008 Joined the Financial Services Agency (fixed-term staff) Financial Securities Inspector, Inspection Coordination Division, Inspection Bureau, Financial Services Agency
• January 2010 Specialist Inspector, Inspection Coordination Division, Inspection Bureau, Financial Services Agency
• June 2010 Special Inspector, Inspection Coordination Division, Inspection Bureau, and Assistant Director, Policy and Legal Division, Planning and Coordination Bureau, Financial Services Agency
• December 2010 Resigned from the Agency
• July 2013 Partner, Habataki Law Office (current position)
• June 2018 Outside Audit & Supervisory Board Member of ShinMaywa Industries, Ltd. (current position)
• April 2022 Professor of Legal Practice, Graduate School of Law, Kobe University (current position)
• June 2023 Outside Executive Director (current position)

• October 1989 Joined Asahi Shinwa Accounting Firm (currently KPMG AZSA LLC)
• August 1993 Registered as a certified public accountant
• March 2001 Established Satoko Nishimura Certified Public Accountant Office and assumed the position of Representative (current position)
• October 2002 Registered as a certified public tax accountant Established Satoko Nishimura Certified Public Tax Accountant Office and assumed the position of Representative (current position)
• February 2023 Outside Director (Audit and Supervisory Committee Member) of Zojirushi Corporation (current position)
• June 2023 Outside Executive Director (current position)

• April 1978 Joined Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
• June 2001 Director of Human Resources Department of Fujisawa Pharmaceutical Co., Ltd.
• April 2005 Director in charge of Human Resources Department of Astellas Pharma Inc.
• April 2007 Chief of Secretarial Office of Astellas Pharma Inc.
• April 2008 Vice President, Head of Human Resources Department of Astellas Pharma Inc.
• June 2009 Executive Officer and Director of Human Resources Department of Astellas Pharma Inc.
• June 2013 Executive Officer and General Manager of Human Resources Division of DAISO CO., LTD. (currently OSAKA SODA CO., LTD.)
• April 2015 Executive Officer and General Manager of Human Resources Division and Director of Corporate Planning Department, Corporate Strategy Division of DAISO CO., LTD.
• April 2016 Executive Officer and General Manager of Human Resources Division and Director of Human Resources Development Department, Human Resources Division and Director of Corporate Planning Department, Corporate Strategy Division of OSAKA SODA CO., LTD.
• April 2017 Executive Officer Director in charge of Human Resources Division and Corporate Planning Department, Corporate Strategy Division of OSAKA SODA CO., LTD.
• June 2017 Full-time Audit & Supervisory Board Member of the Company
• July 2019 Audit & Supervisory Board Member of LINICAL TAIWAN CO., LTD. (current position) Audit & Supervisory Board Member of LINICAL KOREA CO., LTD. (current position)
• December 2019 Audit & Supervisory Board Member of Linical China Co., Ltd. (current position)
• June 2023 Full-time Audit and Supervisory Committee Member (Outside Executive Director) (current position)

• April 1981 Joined Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
• April 2011 Vice President, Head of Accounting & Tax Department of Astellas Pharma Inc.
• June 2013 Vice President, Head of Accounting & Tax Department of Astellas Pharma Inc. and Audit & Supervisory Board Member of Amgen Astellas BioPharma KK (currently Amgen Inc.)
• July 2017 Joined Marvelous Inc.
• October 2017 Director of Accounting and Finance Department, Administration Division of Marvelous Inc.
• November 2017 Audit & Supervisory Board Member of G-Mode Corporation
• July 2020 Full-time Audit & Supervisory Board Member of the Company
• June 2023 Full-time Audit and Supervisory Committee Member (Outside Executive Director) (current position)

• April 1982 Joined Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
• January 2009 Vice President, Head of Clinical Development Department II, Development Division of Astellas Pharma Inc.
• October 2011 Corporate Vice President in charge of Development Division of Toyama Chemical Co., Ltd.
• June 2012 Senior Vice President, Head of Development Division and Deputy Head of Business Strategy Office of Toyama Chemical Co., Ltd.
• April 2013 Senior Vice President, Head of Clinical Development Office of Toyama Chemical Co., Ltd.
• June 2015 Executive Director and Senior Vice President, Head of Clinical Development Office of Toyama Chemical Co., Ltd.
• April 2017 Executive Director and Senior Vice President and Assistant to the President and Head of Clinical Development Office of Toyama Chemical Co., Ltd.
• October 2018 Executive Director and Senior Vice President, Head of Development Division of FUJIFILM Toyama Chemical Co., Ltd.
• July 2021 Full-time Audit & Supervisory Board Member of the Company
• June 2023 Full-time Audit and Supervisory Committee Member (Outside Executive Director) (current position)

• Established Linical in 2005 as one of the co-founders
• Leads the Linical Group as one of the HQs' Board members (2007 to 2024), Linical Americas organization (2018 to 2020 and 2023), Linical Europe organization (2021 to 2022), ensuring commitment to and compliance with all applicable laws and regulations across the organization as well as contributing global operations with close and timely communications with HQs and the other affiliates
• Ph.D. of Medicine from Kobe University and Master of Science, Pharmaceutical Sciences from Tokyo University of Pharmacy and Life Sciences

After graduating from Kyoto Pharmaceutical University, Mr. Kawai completed a Master’s degree at the Graduate School of Pharmaceutical Science of the same university. After joining the Research Division of Nihon Shearing K.K., he worked on pharmaceutical product development at Meditech International Co., Ltd., SmithKline Beecham Co., Ltd., and Shionogi & Co., Ltd.

In December 2006, he joined Linical then has contributed to the company’s globalization effort when he served as Supervisory Director of the Asian Region since June 2016. Then, he became Director of US Business in December 2020. In May 2021, he became Director, President & CEO of Linical USA, Inc. In Jan 2023 he served as Director & CEO, Linical Europe Holding GmbH. He assumed his current position in June 2024.

Mr. Takahashi earned a Master’s degree at the Graduate School of Medical Sciences at the University of Tsukuba. He worked at the Research Laboratories of Toyama Chemical Co., Ltd., at Medi-Tech International Corporation, and at Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.). Since April 2007 he has served as CFO at Linical, after joining as a co-founder. He was registered as an SME management consultant in 2010. 

After graduating from Kobe Pharmaceutical University, Ms. Yamaguchi worked as a hospital pharmacist at a medical institution in Osaka. In 2000, she started working in development support as a temporary employee at Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.). Later, while engaged in CRC tasks at an SMO, she was appointed as a temporary auditor at Linical when the company was newly established in 2005. In 2007, she became a Linical employee and was put in charge of the Internal Audit Office (now “Audit Office”). She has served as Chief Compliance Officer (CCO) since 2009.

• April 1987 Joined Konishiroku Photo Industry Co., Ltd. (currently Konica Minolta, Inc.).
• May 2004 Director, IT Planning of Konica Minolta Business Solutions U.S.A., Inc..
• April 2013 Senior Manager, IT Infrastructure Technologies, System Development and Infrastructure Service Division of Konica Minolta Information System Co., Ltd.
• April 2017 Senior Manager, Corporate Planning Department of Konica Minolta Information System Co., Ltd.
• July 2022 Joined Linical CO., Ltd. as Chief Information Officer

After graduating from the School of Pharmaceutical Sciences at Kyoto Pharmaceutical University, Mr. Tsujimoto worked as a CRA at a Japanese pharmaceutical company, then in 2002 began working as a development manager at a foreign pharmaceutical company. He joined Linical in 2008 to serve as an Executive Vice President. Later, he served as CEO of Linical USA. In 2015, he also became the CEO of Linical Europe. After returning from Europe in December 2020, he served as Chairman of Linical Europe & Americas, and International Business Manager. He assumed his current position in June 2024.

• After graduating from the School of Pharmaceutical Sciences at Kyoto Pharmaceutical University, Mr. Miyazaki earned a Master’s degree in Pharmacology at the same university.
• After a stint as a CRA in Japan, in 1999 he started working on the development of immunosuppressant drugs in the Development Division of Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.).
• From 2003, he worked as a project leader on fertility and anticancer drugs at a foreign pharmaceutical company.
• In 2005, he co-founded Linical and on the opening of the Tokyo office in 2006 was appointed a director of the company.
• After serving as head of the Development division, Mr. Miyazaki assumed the position of Executive Vice President, Asia and President and CEO of Taiwan in December 2020.
• He assumed his current position in June 2024.

• +30 years of experience in the pharmaceutical and CRO industry in Japan and the US.
• +6 years of experience at Linical Co., Ltd. (Osaka, Japan) in leading IDDB and providing +30 mid-sized pharma and biotech companies with the following services: market/gap analysis, medical writing, regulatory, PMDA consultation, CTN, ICCC, NDA, and strategic partnering/licensing.
• 8 years of experience with licensing/business development and corporate planning at Shionogi & Co. and made 5 licenses and 1 M&A deals.
• 7 years of experience with clinical monitoring, project management and regulatory strategy for the products to treat brain diseases at Shionogi & Co. and its subsidiary in NJ, USA.
• 13 years of experience with drug discovery & neuroscience research at Chugai Pharmaceuticals, Visiting Researcher at Departments of Neurology and Neurological Surgery, University of California at San Francisco, USA and Visiting Professor at Department of Molecular Neuropathology, Brain Research Institute, Niigata University, Japan.
• Ph.D. (Pharmaceutical Sciences) from Hiroshima University